KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Gross Profit: 2013-2025

Historic Gross Profit for Supernus Pharmaceuticals (SUPN) over the last 12 years, with Sep 2025 value amounting to $173.1 million.

  • Supernus Pharmaceuticals' Gross Profit rose 9.51% to $173.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $603.9 million, marking a year-over-year increase of 4.02%. This contributed to the annual value of $583.9 million for FY2024, which is 11.49% up from last year.
  • According to the latest figures from Q3 2025, Supernus Pharmaceuticals' Gross Profit is $173.1 million, which was up 16.49% from $148.6 million recorded in Q2 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Gross Profit peaked at $173.1 million during Q3 2025, and registered a low of $114.5 million during Q2 2023.
  • Over the past 3 years, Supernus Pharmaceuticals' median Gross Profit value was $144.7 million (recorded in 2023), while the average stood at $142.1 million.
  • Its Gross Profit has fluctuated over the past 5 years, first declined by 23.48% in 2023, then soared by 31.39% in 2024.
  • Over the past 5 years, Supernus Pharmaceuticals' Gross Profit (Quarterly) stood at $142.1 million in 2021, then rose by 1.63% to $144.4 million in 2022, then climbed by 0.22% to $144.7 million in 2023, then climbed by 2.33% to $148.1 million in 2024, then climbed by 9.51% to $173.1 million in 2025.
  • Its last three reported values are $173.1 million in Q3 2025, $148.6 million for Q2 2025, and $134.1 million during Q1 2025.